36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details

臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01294241 (ClinicalTrials.gov)	October 2010	27/10/2010	Case Series Documentation of Patients With Epidermolysis Bullosa	Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria	Epidermolysis Bullosa Hereditaria	Drug: Sericare®	Birken AG	NULL	Completed	1 Year	95 Years	Both	10	Phase 2	Germany
2	EUCTR2010-019945-24-DE (EUCTR)	24/09/2010	13/07/2010	Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epithelialization of Skin lesions of Patients with Epidermolysis bullosa hereditaria - EBCS-trial	Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epithelialization of Skin lesions of Patients with Epidermolysis bullosa hereditaria - EBCS-trial	This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelialization of skin lesions of patients with Epidermolysis bullosa hereditaria.	Product Name: Sericare INN or Proposed INN: triterpene dry extract from birch cork	Birken GmbH	NULL	Not Recruiting			Female: yes Male: yes			Germany